Advancing Research to Prevent Suicide Act

The Advancing Research to Prevent Suicide Act (H.R. 4704) was signed into law by The President on January 13, 2021, during the 116th Congress. The law directs the National Science Foundation (NSF) to award competitive, merit-reviewed grants to institutions of higher education for multidisciplinary fundamental research with potential relevance to suicide prevention and treatment. The bill does not authorize or appropriate any specific dollar amount; it is an authorization bill that establishes a grant program subject to the availability of appropriations. Since the bill is already enacted, there is no current legislative momentum or pending action that would affect markets. The law's focus on basic research at universities does not directly create revenue streams for publicly traded companies. No specific companies are named or directly impacted by the grant program. The research areas—human social behavior, neural basis of cognition, human development, perceptual processes, and drug/alcohol abuse—are broad academic fields without direct commercial application in the near term. There are no related bills, amendments, or procurement signals that create convergence with current market activity. The bill's impact on markets is negligible, as it does not change regulatory frameworks, create tax incentives, or mandate corporate behavior.